Advertisement

Topics

Bial and Eisai Company Profile

09:02 EDT 20th September 2017 | BioPortfolio

Founded in 1924, Bial is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal.


News Articles [143 Associated News Articles listed on BioPortfolio]

Bial and Eisai report positive results from Phase II trial of Zebinix for epilepsy

Bial and Eisai have reported a positive outcome from a Phase II clinical trial (Study 208) of Zebinix (eslicarbazepine acetate) in children with focal-onset epilepsy.

Real-world data prove efficacy of Eisai and Bial's epilepsy treatment

Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset epilepsy in adults, as part of a post-market study of mor...

Bial’s epilepsy drug shows clinical efficacy in real-life study

Bial and its licensee Eisai have reported positive real-life data of Zebinix (eslicarbazepine acetate) from the Euro-Esli study in patients with partial-onset seizures (POS).

European approval for novel Eisai epilepsy monotherapy

Eisai and Bial have revealed that their drug Zebinix (eslicarbazepine acetate) has been awarded marketing authorisation by the European Commission as a monotherapy for the treatment of adults with new...

Monotherapy approved to treat epilepsy in Europe

Portugal's largest drugmaker Bial and Japanese pharma major Eisai have announced approval from the European…

No harm to brain function from Zebinix/Aptiom, data shows

Portuguese pharma firm BIAL and Japan’s Eisai have announced data from a Phase II study which showed…

EU regulators widen approval for Zebinix

The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, ...

La Commission européenne a accordé une autorisation de mise sur le marché à Zebinix® ...

Bial et Eisai ont annoncé aujourd'hui que l'Agence européenne des médicaments (EMA) a autorisé l'utilisation de Zebinix ® (acétate d'eslicarbazépine) en monothérapie dans le traitement Re...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Halaven [Eisai Inc.]

These highlights do not include all the information needed to use HALAVEN™ safely and effectively. See full prescribing information for HALAVEN. HALAVEN™ (eribulin mesylate) Injection For intraven...

Lusedra [Eisai, Inc]

These highlights do not include all the information needed to use LUSEDRA safely and effectively. See full prescribing information for LUSEDRA. LUSEDRA (fospropofol disodium) Injection, for intravenou...

Ontak [Eisai, Inc]

These highlights do not include all the information needed to use Ontak safely and effectively. See full prescribing information for Ontak. ONTAK (denileukin diftitox) Injection for intravenous infusi...

Hexalen [Eisai Inc.]

HEXALEN (ALTRETAMINE) CAPSULES 50 mg R Only

Targretin [Eisai Inc.]

Targretin® (bexarotene) capsules, 75 mg

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

About fundamentals and sermonizers. Author's response to the letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?"

The Bial 10-2474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials.

BIA 10-2474 (a fatty acid amide hydrolase inhibitor) was evaluated in a first-in-human phase 1 study in normal volunteers to assess safety/tolerability, pharmacokinetics, pharmacodynamics, and food ef...

A Novel Uncultured Bacterium of the Family Gallionellaceae: Description and Genome Reconstruction Based on the Metagenomic Analysis of Microbial Community in Acid Mine Drainage.

Drainage waters at the metal mining areas often have low pH and high content of dissolved metals due to oxidation of sulfide minerals. Extreme conditions limit microbial diversity in- such ecosystems....

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA...

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets to Eisai's Aciphex® delayed-release 20 mg tablets following a...

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union (EU) for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of ...

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is cond...

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Treatment of triple negative breast cancer (TNBC) relies heavily on different regimes of chemotherapeutic agents but remains one of the most challenging subtypes to treat because of the la...

Companies [15 Associated Companies listed on BioPortfolio]

Bial and Eisai

Founded in 1924, Bial is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is...

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

More Information about "Bial and Eisai" on BioPortfolio

We have published hundreds of Bial and Eisai news stories on BioPortfolio along with dozens of Bial and Eisai Clinical Trials and PubMed Articles about Bial and Eisai for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bial and Eisai Companies in our database. You can also find out about relevant Bial and Eisai Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record